The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with >5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved survival in relapse and refractory AML. As FLT3 status is known to be dynamic, with acquisition, loss, and swapping of FLT3 mutational status seen in a significant number of patients - especially after first-line midostaurin use - it will be important to confirm FLT3 positivity prior to Gil or Quiz therapy, especially in relapsed patients.
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
Establish if FLT3 testing behavior in relapsed AML has evolved.
Establish if FLT3 testing behavior in relapsed AML has evolved.
25 June, 2019
